Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 3, 2006, Pages 254-259

  Garzotto, Mark ^a,b   Myrthue, Anne ^c   Higano, Celestia S ^d   Beer, Tomasz M ^c  

^a PORTLAND VA MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Advanced prostate cancer; Chemotherapy; Docetaxel; Mitoxantrone; Neoadjuvant

Indexed keywords

DOCETAXEL; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HIGH RISK BEHAVIOR; HUMAN; HUMAN TISSUE; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOXANTRONE; NEOADJUVANT THERAPY; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; TAXOIDS; TREATMENT OUTCOME;

EID: 33646173163     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.11.034     Document Type: Review

References (31)

1. Lau W.K., Bergstralh E.J., Blute M.L., et al. Radical prostatectomy for pathological Gleason 8 or greater prostate cancer. Influence of concomitant pathological variables. J Urol 167 (2002) 117-122
2. Pound C.R., Partin A.W., Eisenberger M.A., et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591-1597
3. Aus G., Abrahamsson P.A., Ahlgren G., et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy. A 7-year follow-up of a randomized controlled trial. BJU Int 90 (2002) 561-566
4. Hurtado-coll A., Goldenberg S.L., Klotz L., et al. Preoperative neoadjuvant androgen withdrawal therapy in prostate cancer. The Canadian experience. Urology 60 Suppl 1 (2002) 45-51
5. Soloway M.S., Pareek K., Sharifi R., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer. 5-year results. J Urol 167 (2002) 112-116
6. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
7. Roach III M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression. Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
8. Roach M., Lu J., Pilepich M.V., et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys 47 (2000) 609-615
9. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study). A phase III randomised trial. Lancet 360 (2002) 103-106
10. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
11. Bauer J.J., Connelly R.R., Seterhenn I.A., et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 159 (1998) 929-933
12. Bauer J.J., Connelly R.R., Seterhenn I.A., et al. Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer. Mil Med 163 (1998) 615-619
13. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol 17 (1999) 168-172
14. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
15. Beer T.M., Garzotto M., Lowe B.A., et al. Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 10 (2004) 1306-1311
16. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer. A randomized controlled trial. JAMA 292 (2004) 821-827
17. Dreicer R., Magi-Galluzzi C., Zhou M., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 63 (2004) 1138-1142
18. Eastham J.A., Kelly W.K., Grossfeld G.D., et al. Cancer and Leukemia Group B (CALGB) 90203. A randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 62 Suppl 1 (2003) 55-62
19. Oh W.K., George D.J., Kaufman D.S., et al. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer. A preliminary report. Semin Oncol 28 Suppl 15 (2001) 40-44
20. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer. findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 (1997) 2483-2493
21. Tannock I.F., Osoba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer. A Canadian randomized trial with palliative end points. J Clin Oncol 14 (1996) 1756-1764
22. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
23. Ahmed S., Johnson C.S., Rueger R.M., et al. Calcitriol (1,25-dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol 168 (2002) 756-761
24. Miyake H., Hara S., Arakawa S., et al. Optimal timing and dosage of chemotherapy as a combined treatment with androgen withdrawal in the human prostate LNCaP tumour model. Br J Cancer 84 6 (2001) 859-863
25. Gleave M.E., Miayake H., Goldie J., et al. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides. Urology 54 Suppl 6A (1999) 36-46
26. Kraus L.A., Samuel S.K., Schmid S.M., et al. The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation. Invest New Drugs 21 (2003) 259-268
27. Stearns M.E., and Wang M. Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 52 (1992) 3776-3781
28. Zincke H., Lau W., Bergstralh E., et al. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 166 (2001) 2208-2215
29. Messing E.M., Manola J., Sarosdy M., et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781-1788
30. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
31. Hussain M., Smith D.C., El-Rayes B.F., et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer. Urology 61 (2003) 774-780